Springer Seminars in Immunopathology

, Volume 20, Issue 1–2, pp 247–259 | Cite as

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody

  • Kazuyuki Yoshizaki
  • Norihiro Nishimoto
  • Masahiro Mihara
  • Tadamitsu Kishimoto
Article

Keywords

Rheumatoid Arthritis Arthritis Internal Medicine Signal Transduction Receptor Antibody 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andus T, Geiger T, Hirano T, Northoff H, Ganter U, Bauer J, Kishimoto T, Heinrich PC (1987) Recombinant human B cell stimulatory factor 2 (BSF-2/IFNβ2) regulates β-fibrinogen and albumin mRNA levels in Fao-9 cell. FEBS Lett 221:18Google Scholar
  2. 2.
    Asano S, Okano A, Ozawa K, Nakahata T, Ishibashi T, Koike K, Kimura H, Tanioka Y, Shibuya A, Hirano T, Kishimoto T, Takaku R, Akiyama Y (1990) In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelet. Blood 75: 1602Google Scholar
  3. 3.
    Bakker NPM, Van Erick MG, Botman CAD, Jonker M, Thart BA (1991) Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum 34:616Google Scholar
  4. 4.
    Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M (1996) Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra arthritis study group. Arthritis Rheum 39:1092Google Scholar
  5. 5.
    Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC (1988) Recombinant human interleukin-6 (IL-6BSF-2/HFS) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232: 347Google Scholar
  6. 6.
    Cathcart ES, Hayes KC, Gonnerman WA, Lazzari AA, Franzblau C (1986) Experimental arthritis in a nonhuman primate. Lab Invest 54: 26Google Scholar
  7. 7.
    Ceuppens JL, Baroja ML, Lorre K, Van Damme J, Billiau A (1988) Human T cell activation with phytohemmagglutinin: the function of IL-6 as an accessory signal. J Immunol 141:3868Google Scholar
  8. 8.
    Courtenay JS Dallman MJ Dayan AD, Martin A, Mosedale B (1980) Immunization against heterologous type II collagen induced arthritis in mice. Nature 283: 666Google Scholar
  9. 9.
    Elliott MJ, Maini RN, Feldmann M, Kalden J, Antoni C, Smolen J, Leeb B, Breedveld F, Macfarlane J, Biji H, Woody J (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105Google Scholar
  10. 10.
    Evans J, Yocum E, Maricic M, Gluck O, Tesser J, Chen Z, Baylink J, Fletcher M (1997) Results of an open label, dose-ranging, safety and pharmacokinetic trial of the humanized tumor necrosis factor antibody (HTA), bay 103356, in patients with active rheumatoid arthritis (RA). Arthritis Rheum 40: S224Google Scholar
  11. 11.
    Feldmann M, Elliott MJ, Woody JN, Maini RN (1997) Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 64:283Google Scholar
  12. 12.
    Garman RD, Jacobs KA, Clark SC, Raulet DH (1987) B cell-stimulatory factor 2 (β2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci USA 84:7629Google Scholar
  13. 13.
    Gauldie J, Richards C, Harnish D, Landsdorp P, Baumann H (1987) Interferon (32B cell-stimulatory factor type 2 shares identity with monocyte-derived hepatocytesimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251Google Scholar
  14. 14.
    Gordon C, Richards N, Howie AJ, Richardson K, Michael J, Adu D, Emery P (1991) Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol 86:145Google Scholar
  15. 15.
    Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB (1989) Interleukin 6 is expressed in high levels in psoriasis skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 86:6367Google Scholar
  16. 16.
    Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149Google Scholar
  17. 17.
    Hill RJ, Warren MK, Levin J (1990) Stimulation of thrombopoiesis in mice by human recombinant interleukin-6. J Clin Invest 85:1242Google Scholar
  18. 18.
    Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun K, Kishimoto T (1985) Purification to homogeneity and characterization of human B cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 82:5490Google Scholar
  19. 19.
    Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Kayama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B cell lymphocytes to produce immunoglobulin. Nature 324: 73Google Scholar
  20. 20.
    Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maim R, Feldman M, Kishimoto T (1988) Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18: 1797Google Scholar
  21. 21.
    Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y, Yoshizaki K, Hirano T, Kishimoto T (1989) Involvement of interleukin-6 in mesangial proliferation of glomerulonephritis. J Immunol 143:3949Google Scholar
  22. 22.
    Houssiau FA, Devogelaer JP, Van Damme J, De Deuxchaisies CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. Arthritis Rheum 31:784Google Scholar
  23. 23.
    Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M (1987) Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 84:9035Google Scholar
  24. 24.
    Ishibashi T, Kimura H, Shikawa H, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y (1987) Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 86:5953Google Scholar
  25. 25.
    Ishibashi T, Kimura H, Shikawa Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y (1989) Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241Google Scholar
  26. 26.
    Isshiki H, Akira S, Sugita T, Nishio Y, Hashimoto S, Pawlowski T, Suematsu S, Kishimoto T (1991) Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: possible involvement of NF-IL6 in acute phase protein gene expression. New Biologist 3:63–70Google Scholar
  27. 27.
    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83Google Scholar
  28. 28.
    Klein B, Zhang XG, Jourdan MJC, Houssiau F, Aarden L, Piechaczyk M, Bataille R (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517Google Scholar
  29. 29.
    Koike K, Nakahata T, Takagi M, Kobayashi T, Ishiguro A, Tsujii K, Naganuma K, Okano A, Akiyama Y, Akabane T (1988) Synergism of BSF2/interleukin-6 and interleukin-3 on development of multipotential hemopoietic progenitors in serum free culture. J Exp Med 168: 879Google Scholar
  30. 30.
    Koike K, Nakahata T, Kubo T, Kikuchi T, Takagi M, Ishiguro A, Tsuji K, Naganuma K, Okano A, Akiyama Y, Akabane T (1990) Interleukin-6 enhances murine megakariocytopoiesis in serum-free culture. Blood 75: 2286Google Scholar
  31. 31.
    Le J, Fredrickson G, Reis L, Diamantsein T, Hirano T, Kishimoto T, Vilcek J (1988) Interleukin-2-dependent and interleukin-2-independent pathways of regulation of thymocyte function by interleukin-6. Proc Natl Acad Sci USA 85: 8643Google Scholar
  32. 32.
    Leary A, Ikebuchi K, Hirai Y, Wong G, Yang Y-C, Clark S, Ogawa M (1988) Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1a. Blood 71:1759Google Scholar
  33. 33.
    Lotz M, Jirik F, Kabouridis R, Tsoukas C, Hirano T, Kishimoto T, Carson D (1988) BSF-2/IL-6 is costimulant for human thymocytes and T lymphocytes. J Exp Med 167: 1253Google Scholar
  34. 34.
    Madhok R, Crilly A, Watson J, Capell HA (1993) Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52: 232Google Scholar
  35. 35.
    Maini R, Paulus H, Breedveld F, Charles P, Davies D, Grint P, Wherry J, Feldman M (1997) rHUIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum 40: S224Google Scholar
  36. 36.
    Mihara M, Kotoh M, Oda Y, Kumagai E, Takagi N, Tsunemi K, Takeda Y (1997) Anti-IL-6 receptor antibody suppress the onset of collagen arthritis in monkeys. Arthritis Rheum 40: S133Google Scholar
  37. 37.
    Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T (1993) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808Google Scholar
  38. 38.
    Nijsten MWN, Degroot ER, TenDuis HJ, Klasen J, Hack CE, Aarden LA (1987) Serum levels of interleukin-6 and acute phase responses. Lancet II: 921Google Scholar
  39. 39.
    Nishimoto N, Yoshizaki K, Tagoh H, Monden M, Kishimoto S, Hirano T, Kishimoto T (1989) Elevation of serum interleukin-6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 50: 399Google Scholar
  40. 40.
    Noma T, Mizuta T, Rosen A, Hirano T, Kishimoto T, Honjo T (1987) Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett 15: 249Google Scholar
  41. 41.
    Nordan RP, Pumphrey JG, Rudikoff S (1987) Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the routine macrophage cell line P388D1. J Immunol 139: 813Google Scholar
  42. 42.
    Nuki G, Rozman B, Pavelka K, Emery P, Lookabaugh J, Musikic P (1997) Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum 40: S224Google Scholar
  43. 43.
    Numata Y, Matsuura Y, Onishi S, Yamamoto Y, Ohno F, Tagoh H, Yoshizaki K, Fujimoto S, Yamamoto H (1991) Case report: interleukin-6 positive follicular hyperplasia in the lymph node of a patient with rheumatoid arthritis. Am J Hematol 36: 282Google Scholar
  44. 44.
    Ogawa M (1993) Differentiation and proliferation of hematopoietic stem cells. Blood 81: 2844Google Scholar
  45. 45.
    Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monoden M, Gotoh M, Kishimoto T, Mori T (1992) Interleukin-6 as a new indicator for the inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein following surgical operation. Surgery 111: 201Google Scholar
  46. 46.
    Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T (1988) BSF-2/IL-6 functions as killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 141: 1543Google Scholar
  47. 47.
    Rubin AS, Healy CT, Martin LN, Baskin GB, Roberts ED (1987) Experimental arthropathy induced in rhesus monkeys (Macaca mulatta) by intradermal immunization with native bovine type II collagen. Lab Invest 57: 524Google Scholar
  48. 48.
    Sack U, Kinne R, Marx T, Heppt P, Bender S, Emmrich F (1993) Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 13: 45Google Scholar
  49. 49.
    Sander O, Rau R (1997) Long term observation of 80 patients treated with TNFα receptor-fusion protein (TNFR55-GG1, RO 45-2081). Arthritis Rheum 40:S224Google Scholar
  50. 50.
    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851Google Scholar
  51. 51.
    Smith HS, Steinberg AD (1983) Autoimmunity — a perspective. Annu Rev Immunol 1: 175Google Scholar
  52. 52.
    Stanley ER, Bartocci A, Patinkin D, Rosendaal M, Bradley TR (1986) Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1. Cell 45:667Google Scholar
  53. 53.
    Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 86: 7547Google Scholar
  54. 54.
    Sugita T, Furukawa O, Ueno M, Murakami T, Takata I, Tosa T (1993) Enhanced expression of interleukin-6 in rat and murine arthritis models. Int J Immunopharmacol 15:469Google Scholar
  55. 55.
    Takai Y, Wong GG, Clark SC, Burakoff SJ, Herrmann SH (1988) B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 140: 508Google Scholar
  56. 56.
    Takai Y, Seki N, Senoh H, Yokota T, Lee F, Hamaoka T, Fujiwara T (1989) Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. Arthritis Rheum 32:594Google Scholar
  57. 57.
    Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 90: 11924Google Scholar
  58. 58.
    Terato K, Arai H, Shimozuru Y, Fukuda T, Tanaka H, Watanabe H, Nagai Y, Fujimoto K, Okubo F, Cho F, Honjo S, Cremer MA (1989) Sex-linked differences in susceptibility of cynomolgus monkeys to type II collagen-induced arthritis. Evidence that epitope-specific immune suppression is involved in the regulation of type II collagen autoantibody formation. Arthritis Rheum 32: 748Google Scholar
  59. 59.
    Tomita T, Takeuchi E, Tomita N, Morishita R, Hashimoto H, Kaneko M, Yamamoto K, Kameda Y, Ochi T (1997) In vivo transfection of NF-κB decoy reduced severity of rat collagen-induced arthritis as a gene therapy. Arthritis Rheum 40: S220Google Scholar
  60. 60.
    Trentham DE (1982) Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum 25: 911Google Scholar
  61. 61.
    Trentham DE, Townes AS, Kang AH (1977) Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 146: 857Google Scholar
  62. 62.
    Van Damme J, Opdenakker G, Simpson RJ, Rubia MR, Cayphas S, Vink A, Billiau A, Van Snick JV (1987) Identification of the human 26-kDa protein, interferon β2 (IFNb2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 165:914Google Scholar
  63. 63.
    Van Den Berg WB, Joosten LAB, Helsen M, Van De Loo FAJ (1994) Amelioration of established routine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95: 237Google Scholar
  64. 64.
    Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20: 259Google Scholar
  65. 65.
    Williams RO, Feldman M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784Google Scholar
  66. 66.
    Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602Google Scholar
  67. 67.
    Yamazaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFNβ2) receptor. Science 241: 825Google Scholar
  68. 68.
    Yoo TJ, Kim S-Y, Stuart JM, Floyd RA, Olson GA, Cremer MA, Kang AH (1988) Induction of arthritis in monkeys by immunization with type II collagen. J Exp Med 168:777Google Scholar
  69. 69.
    Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T (1982) Induction of proliferation and Igs-production in human B leukemic cells by anti-immunglobulins and T cell factors. J Immunol 128:1296Google Scholar
  70. 70.
    Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Lee T, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T (1989) Pathogenic significance of interleukin-6(IL-6BSF-2) in Castleman's disease. Blood 74: 1360Google Scholar
  71. 71.
    Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y, Kuritani T, Hirano T, Kishimoto T (1990) Interleukin-6 and its receptor expression on the epidermal keratinocytes. Cytokine 2: 281Google Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • Kazuyuki Yoshizaki
    • 1
  • Norihiro Nishimoto
    • 1
  • Masahiro Mihara
    • 2
  • Tadamitsu Kishimoto
    • 3
  1. 1.Department of Medical Science I, School of Health and Sport SciencesOsaka UniversityOsakaJapan
  2. 2.Fuji-Gotenba LaboratoriesChugai Pharmaceutical Co. LtdShizuokaJapan
  3. 3.President of Osaka UniversityOsakaJapan

Personalised recommendations